Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

1. Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.The Journal of antimicrobial chemotherapy · 2015
   Trial
2. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.Virus research · 2020
   Review
3. The Challenges and Promise of HIV-Infected Donors for Solid Organ Transplantation.Current infectious disease reports · 2015
   Article
4. [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2014
   Review
5. Organ Transplantation in HIV Patients: Current Status and New Directions.Current infectious disease reports · 2013
   Article

Corrections and comments

• Comment on
  Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.2012

Authors and funding

7 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as